ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0492

Effect of Microbiome Modulation on Urinary Citrate and pH

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1101 Fluid, Electrolyte, and Acid-Base Disorders: Basic

Authors

  • Jaber, Karim, NYU Langone Health, New York, New York, United States
  • Mishra, Rashmi, NYU Langone Health, New York, New York, United States
  • Xiong, Xiaozhong, NYU Langone Health, New York, New York, United States
  • Charytan, Amalya M., NYU Langone Health, New York, New York, United States
  • Merritts, Kyle, NYU Langone Health, New York, New York, United States
  • Nazzal, Lama, NYU Langone Health, New York, New York, United States
Background

The gut microbiome plays an important role in the pathogenesis of urinary stone disease (USD), potentially through its influence on urinary components associated with stone formation. Changes in urinary pH and citrate levels are well established risk factors for USD. This study aims to determine the effects of microbiome suppression and subsequent restoration on urinary citrate concentration and pH, thereby elucidating the potential microbiome's contribution.

Methods

Twenty-four male C57BL/6 mice were randomly assigned to receive placebo, sulfamethoxazole, or tylosin (n=8 per group). Baseline urine samples were collected over 24 hours prior to treatment initiation and again after one week of treatment. Antibiotics were subsequently discontinued, and the treated mice were co-housed with untreated mice for three weeks to allow microbiome restoration, after which a final urine sample was collected. Urinary citrate levels were measured using liquid chromatography–mass spectrometry (LC/MS) at the three timepoints, and urinary pH was assessed using a pH meter baseline and one week after antibiotic treatment.

Results

Tylosin treatment significantly reduced urinary pH (6.72±0.35 to 5.93±0.34, p<0.01), whereas sulfamethoxazole had no significant effect (6.77±0.2 to 6.59±0.4, p=0.81) (Fig. 1). Urinary citrate excretion increased significantly in the sulfamethoxazole group (0.149±0.07 mg/24h to 0.404±0.16 mg/24h, p<0.01). Following co-housing with healthy mice, urinary citrate returned to its baseline value in both groups (Fig. 2).

Conclusion

Antibiotic-induced suppression of the gut microbiome led to antibiotic-specific changes in urinary citrate levels and pH, both key factors influencing USD risk. Partial restoration of the healthy microbiome reversed these alterations in urinary citrate. Further studies are necessary to identify the specific bacterial species responsible for regulating urinary citrate excretion and acid-base balance.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)